Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzalkonium chloride/octoxynol vaginal gel - Optima

Drug Profile

Benzalkonium chloride/octoxynol vaginal gel - Optima

Alternative Names: Alkyldimethylbenzylammonium chloride (ADBAC)/octoxynol - Optima; Benzalkonium chloride/octoxynol 9; Contraceptive gel - Optima Worldwide; Octoxynol 9/benzalkonium chloride; Octoxynol/benzalkonium chloride; Prevent-X; Surete

Latest Information Update: 01 Oct 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Optima Worldwide
  • Developer OmniComm Systems; Optima Worldwide
  • Class Antiseptics; Benzylammonium compounds; Contraceptives; Polyethylene glycols; Quaternary ammonium compounds; Spermicidal contraceptives; Surfactants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy
  • Discontinued HIV infections

Most Recent Events

  • 27 Dec 2000 Phase-III clinical trials for HIV infections prevention in Brazil (Vaginal)
  • 15 Dec 2000 Phase-III clinical trials for Contraception/Pregnancy (Prevention) in Brazil (Vaginal)
  • 22 Nov 2000 Launched for Contraception/Pregnancy (Prevention) in China (Vaginal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top